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Iron and anemia of chronic disease. Anemia of chronic disease as reflected by ferritin levels, are often increased [3–6].
(ACD) is the most frequent anemia found in hospitalized pa- Transferrin concentrations and reticulocyte counts are
tients, often occurring in subjects suffering from chronic in- normal or somewhat reduced, whereas serum transferrinflammatory disorders. The underlying diversion of iron traffic
receptor (TfR) levels are slightly enhanced [3–7].leads to a withdrawal of the metal from the sites of erythropoie-
Although ACD is probably the most frequent anemiasis and the circulation to the storage compartment in the reticu-
loendothelial system, thus resulting, at the same time, in hypo- in hospitalized patients, the underlying mechanisms are
ferremia and hyperferritinemia. Proinflammatory and anti- still elusive. In addition to various other factors such
inflammatory cytokines, acute-phase proteins, and radicals are as repression of erythropoiesis, a blunted response toprominently involved in causing these disturbances of iron
erythropoietin, and erythrophagocytosis, disturbances ofhomeostasis. The role of these factors, as well as the pathophys-
iron homeostasis appear to be prominently involved iniological reasons for the development of ACD, is discussed in
this review. the development of anemia under chronic inflammatory
conditions [3–6, 8]. This review focuses on mechanisms
that contribute to the diversion of iron traffic underlying
Iron is a Janus-faced molecule that, on one hand, is ACD, leading to the withdrawal of iron from the sites
an essential cofactor for enzymes in the mitochondrial of erythropoiesis and from serum to the iron storage
respiration chain, in the citric acid cycle or for DNA sites in the reticuloendothelial system.
synthesis, as well as a central molecule for binding and
transporting oxygen by hemoglobin and myoglobin [1].
THE TH-1/TH-2 PARADIGM ANDOn the other hand, cellular accumulation of metaboli-
IRON HOMEOSTASIScally active iron may be detrimental to cells and sur-
rounding tissues because iron is also able to catalyze In prior years, evidence has accumulated for the exis-
the formation of highly toxic hydroxyl radicals by the tence of two CD 41 T-helper cell subsets in humans,
“Haber-Weiss” reaction [1, 2]. Therefore, tight regula- each of which produce a typical set of cytokines that
tion of iron homeostasis is an absolute requirement for regulate different immune effector functions and cross-
maintaining essential cellular functions while avoiding react with each other [9–11]. T-helper cells type 1 (Th-1)
cellular damage. Thus far, many proteins, molecules, produce interferon (IFN)-g, interleukin (IL)-2, and lym-
hormones and, last but not least, iron itself have been photoxin [tumor necrosis factor (TNF)-b]. These cyto-
demonstrated to affect iron metabolism by various mech- kines activate macrophages, thus contributing to the for-
anisms at different regulatory levels [1], which is also mation of proinflammatory cytokines, such as TNF-a,
detailed elsewhere in this issue. IL-1, or IL-6, and the induction of cytotoxic immune
Some of these factors may become dominant over effector mechanisms of macrophages. By contrast, Th-2
others in cases of chronic inflammatory diseases, thus cells produce IL-4, IL-5, IL-10, and IL-13, which induce
leading to disturbances of iron metabolism. Therefore, a strong antibody response but also inhibit various mac-
patients suffering from a chronic infectious or tumor rophage functions [9–11].
disease or an autoimmune disorder frequently develop T-helper cells type 1 (Th-1)–derived cytokines have
a moderate anemia, which is termed “anemia of chronic been demonstrated to also affect iron homeostasis by
disease” (ACD). This normochromic/microcytic anemia different mechanisms, although the data available so far
is clinically characterized by reduced serum iron concen- are conflicting.
trations and transferrin saturation, whereas iron stores, Interleukin-1 and TNF-a are able to induce hypofer-
remia by modulating macrophage iron metabolism [12,
13]. This is primarily exerted by an effect of the cytokinesKey words: iron homeostasis, inflammation, hypoferremia, erythropoi-
esis. on the expression of the iron storage protein ferritin [14].
IL-1 and TNF-a increase the expression of L-chain and 1999 by the International Society of Nephrology
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H-chain ferritin by an as yet not fully elucidated tran- ated iron uptake in activated macrophages, which is then
stored in ferritin that has been effectively produced fol-scriptional mechanism [15–17]. In addition, IL-1 and IL-6
increase L- and H-ferritin expression in hepatoma cells lowing stimulation with proinflammatory cytokines.
by a translational mechanism [18, 19]. A limitation of
some of these studies is due to the fact that the described
SHORT-LIVED RADICALS
observations were made in different cell lines (like myo-
Recently, it has been shown that short-lived radicalsblasts, adipocytes, fibroblasts), which is of interest because
such as hydrogen peroxide (H2O2) or nitric oxide (NO)—iron metabolism appears to be differently regulated, for
both of which are produced during inflammatory re-example, between erythroid cells, macrophages, or hepa-
sponses associated with ACD—are able to influence cel-tocytes [1]. For example, it was demonstrated that IL-6
lular iron homeostasis. NO and H2O2 stimulate the bindingenhances TfR expression on hepatocytes, whereas it had
affinity of cytoplasmic proteins (IRPs) to RNA stem loopno effect in Kupffer cells [20], and similarly IL-1 and
structures (IRE) [28–31]. One IRE is present within theTNF-a affect iron uptake by increasing TfR expression
59 untranslated regions of L-ferritin, H-ferritin mRNA, andin fibroblasts [21], whereas just the opposite is true for
erythroid amino-levulinate synthase (e-ALAS) mRNA,monocytic cells [17].
whereas five IREs have been detected within the 39 un-In contrast, IFN-g may rather depress TfR expression
translated region of TfR mRNA [32, 33]. Binding ofby transcriptional and post-transcriptional mechanisms
IRP-1 and IRP-2 to IREs within the 59 untranslated[22–25]. However, the regulation of TfR expression in
region of target mRNAs results in a translational repres-activated macrophages appears to be very complex and
sion of their expression, whereas interaction with thesensitive to experimental differences in the activation,
IREs in the 39 region enhances TfR mRNA stability bydifferentiation, and in vitro stimulation of the macro-
protecting it from digestion by a specific RNase. There-phages investigated by different groups [21–27]. More-
fore, circumstances that stimulate IRE-binding affinityover, in human and murine macrophages, ferritin mRNA
of IRPs, such as NO formation, oxidative stress, or ironexpression is induced by IFN-g [21, 28], whereas at the
deprivation states, enhance iron uptake, whereas ironsame time, a translational repression occurs because of
consumption and iron storage are reduced. In contrast,the formation of the short-lived radical nitric oxide (NO)
increased cellular iron concentrations as well as inhibi-via stimulation of the interaction of iron regulatory pro-
tion of NO or H2O2 formation result in loss of IRE-teins (IRPs) with an RNA stem loop structure, iron re-
binding function of IRPs, thus leading to derepressionsponsive elements (IRE), as detailed later here [25, 28,
of ferritin and eALAS mRNA translation while the TfR29]. This is compatible with observations made in human
mRNA half-life is reduced. This, in turn, leads to ironmacrophages in which IFN-g decreases intracellular fer-
consumption and storage while iron uptake is blockedritin content [23].
[32, 33].In summary, proinflammatory cytokines appear to
It is worth noting that the effects of NO and H2O2 oncause hypoferremia via the induction of ferritin synthesis
IRP activation are of a different nature. While H2O2and iron storage in macrophages and hepatocytes,
activates IRP-1 but not IRP-2 [31] by a poorly under-whereas IFN-g tries to keep iron out of macrophages.
stood fast-reacting mechanism involving kinase/phos-This makes sense, given the inhibitory effects of iron on
phatase pathways, NO stimulates IRE-binding activityIFN-g–mediated pathways (discussed later in this ar-
of both IRPs at least in macrophages with an albeitticle).
slower kinetic, which is comparable to that observedInterestingly, thus far, hardly any attention has been
after pharmacological induction of iron deprivation bypaid to the role of Th-2–derived cytokines on iron ho-
means of iron chelators [34]. This suggests that NO andmeostasis. In activated murine macrophages, IL-4 and
H2O2 may be involved in different regulatory propertiesIL-13 have recently been demonstrated to modulate iron
of iron homeostasis during inflammatory conditions [32,metabolism by two different pathways [25]: (1) by oppos-
34]. Moreover, induction of oxidative stress on additioning IFN-g–mediated IRP activation via NO formation,
of a glutathione-depleting drug to hepatic cells was alsothus increasing ferritin translation; and (2) by an aug-
shown to stimulate ferritin synthesis by a transcriptionalmentation of TfR mRNA expression, which is most likely
mechanisms [35].due to reversing the inhibitory effect of IFN-g on TfR
However, cytokines may overcome the regulatory ef-mRNA transcription. Therefore, Th-2–derived cytokines
fects of these radicals. Apart from other mechanisms,are able to increase iron uptake and storage in activated
oxygen radicals are formed by macrophages stimulatedmacrophages.
with IFN-g, TNF-a and/or lipopolysaccharide (LPS), andFrom this point of view, it appears reasonable that
murine macrophages or human hepatocytes also gener-Th-1– and Th-2–derived cytokines may collaborate in
ate NO after treatment with the same stimuli, due to theinducing hypoferremia/hyperferretinemia in a way that
Th-2–derived cytokines primarily enhance TfR-medi- induction of a cytokine-inducible form of NO synthase
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(NOS type II). Nevertheless, as stated earlier here, these a-1 antitrypsin or a-2 macroglobulin, have been demon-
strated to inhibit TfR-mediated iron uptake into ery-cytokines have also direct effects on iron homeostasis,
acting sometimes proximally from regulation by the IRE/ throid cells and hepatocytes, but not into monocytic cells,
by direct competitive interaction with the TfR [45, 46].IRP system. In activated murine macrophages and hepa-
tocytes producing high amounts of NO after stimulation This may also contribute to the ACD-typical diversion
of iron traffic by favoring iron uptake by monocytic cellswith IFN-g and LPS, ferritin expression is inhibited
translationally due to NO-mediated activation of IRPs, while the metal is withdrawn from the erythron, thus
blocking the proliferation of erythroid progenitors [45].whereas NO is not able to stabilize TfR mRNA under
such conditions [25, 28, 29, 36]. The latter observation Most recently, thyroid hormones have been shown
to modulate hepatic iron metabolism translationally viais due to the fact that IFN-g and LPS act proximally
from the cytoplasmic regulation by the IRE/IRP system stimulation of ferritin synthesis by inducing alterations
of IRE/IRP interactions [47, 48].to inhibit TfR mRNA expression, probably within the
nucleus. Because circulating amounts of stress hormones may
be increased during inflammatory processes, it will beHowever, the question remains of how radicals may
be involved in the development of ACD. The observa- interesting to see to which extent thyroid hormones may
participate in alterations of iron homeostasis occurringtion that iron by itself also modulates the expression of
NOS II by transcriptional mechanisms provided evi- in ACD.
dence for the existence of an autoregulatory loop in
macrophages that links the maintenance of iron homeo-
WHY ANEMIA OF CHRONIC DISEASE?
stasis with the formation of NO [37], which is centrally
Because ACD is very frequently occurring underinvolved in host defense [38]. This loop could serve as
chronic inflammatory conditions, it is tempting to specu-a suitable mechanism for macrophages to acquire and
late about what could be the body’s idea causing thesestore iron under inflammatory conditions, leading to the
diversions of iron traffic that underlie this disease.characteristic diversion of iron underlying ACD [37].
Besides its effect on cellular iron homeostasis, NO
Iron and immunity
may contribute to the development of ACD by other
Iron has multiple effects on cell-mediated immunity.mechanisms. First, NO is able to inhibit heme biosynthe-
On one hand, it differently modulates the proliferationsis. This may be achieved on one hand by NO-mediated
and differentiation of lymphocyte subsets, whereas, onstimulation of high-affinity binding of IRP-1 to the IRE
the other hand, it strongly affects the immune potentialwithin the 59 untranslated region of e-ALAS mRNA,
of macrophages [8, 49, 50]. The latter effects are due inthus resulting in translational repression of e-ALAS
part to an iron-mediated inhibition of IFN-g–directedmRNA expression [39]. On the other hand, NO is able
immune response pathways in macrophages [51]. There-to inhibit ferrochelatase activity in part by targeting its
fore, iron-loaded macrophages exhibit reduced IFN-gcentral iron sulfur cluster [40], which may be another
responsiveness, TNF-a production, and the formation ofmechanism contributing to abnormal heme biosynthesis
NO [8, 37, 50–52], and the immune defense against vari-in inflammation [41]. Second, NO can directly block
ous intracellular pathogens and viruses is impaired undererythropoiesis by inhibiting the proliferation of erythroid
such conditions [53–57]. From this point of view, with-progenitor cells in the bone marrow [42, 43].
drawal of metabolically active iron from the circulationWhether H2O2 may be involved in similar regulatory
and storage of the metal, as it occurs in ACD, wouldloops or have similar effects on e-ALAS expression or
contribute to strengthening the immune response viaerythropoiesis remains to be shown.
stimulation of IFN-g–mediated immune effector mecha-Currently, ongoing studies with NOS II knock-out
nisms.mice will hopefully contribute to the definition of the
On the contrary, IL-4 and IL-13 may reduce Th-1–part NO plays among all other factors orchestrating iron
mediated immune effector function by increasing intra-metabolism under chronic inflammatory conditions.
cellular iron content via stimulation of TfR expression,
which may be part of their anti-inflammatory and macro-
ACUTE PHASE PROTEINS AND HORMONES phage-deactivating function [25].
Some of the activating effects exerted by cytokines
Iron withholdingsuch as IL-1 or IL-6 on ferritin mRNA expression have
been proposed to occur as part of the acute phase re- Because of the multiple functions of iron in metabo-
lism outlined in the beginning of this article, this metalsponse in the liver in order to contribute to detoxification
of iron by promoting its storage, thus preventing the is an essential growth factor for proliferating tissues and
microorganisms. Therefore, withholding iron from in-catalyzation of toxic radical reactions by the metal [17,
19, 44]. Moreover, other acute phase proteins, such as vading pathogens and tumor cells would limit their
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growth by affecting their energy metabolism or DNA diseases for several reasons. On one hand, supplementa-
tion of iron would promote growth and proliferation ofsynthesis [58, 59]. Furthermore, decreased formation of
hemoglobin by withholding iron from the erythron and tumor cells and microorganisms underlying the chronic
inflammatory disease causing ACD [58, 59]; on the otherinhibition of erythropoiesis by cytokines reduces the oxy-
gen transport capacity of the blood, thus decreasing the hand, cell-mediated immune effector mechanisms may
be weakened by the action of iron [8, 37, 50–57]. More-overall oxygen supply that may primarily affect rapid
proliferating (malignant) tissues and microorganisms. over, it is questionable how much iron may pass over
into the erythron due to the withholding mechanism
Other mechanisms outlined in this review. On the contrary, supplementa-
tion of iron to ACD patients with an autoimmune disor-Besides the underlying mechanism of iron perturba-
tions in ACD, other factors not discussed in this review der may be rather beneficial [67, 68], most likely because
of the described inhibitory actions of iron on cytokinemay also contribute to ACD. Bacterial toxins and cyto-
kines, such as TNF-a, have been proposed to decrease actions and macrophage-mediated cytotoxicity, although
the contribution of the metal to the formation of toxicerythrocyte survival and to cause an increased phagocy-
tosis of these cells by splenic macrophages. This is com- radicals has to be taken into account [68]. Interestingly,
recent reports have also suggested using iron chelationpatible with the observation that during inflammatory
states an increase of erythrocyte-derived iron in splenic with desferrioxamine for the treatment of ACD despite
low serum iron concentrations. Such a therapy was asso-macrophages and Kupffer cells takes place [1, 60, 61].
Nevertheless, to date there is no evidence on the extent ciated with a rise in hemoglobin levels, which was attrib-
uted to stimulation of erythropoietin production [69] viato which erythrophagocytosis may play a role in ACD
and the associated disturbances of iron homeostasis, al- induction of the binding of hypoxia regulatory factors
to the erythropoietin promoter.though the release of iron from phagocytosed erythro-
cytes may have distinct, but not yet elucidated, effects Recombinant erythropoietin is a widely used thera-
peutic approach for ACD (discussed in this issue) [6,on the regulation of iron metabolism in macrophages.
62, 63]. However, response rates to the therapy withAlternatively, ACD may just be seen as a disease
erythropoietin are sometimes low. This may refer, inoccurring as a side effect of an ongoing immune response.
part, to the fact that a prominently stimulated immuneCytokines not only affect iron metabolism, as shown
activation will inhibit erythropoiesis very efficiently viaherein, but they also exert inhibitory effects on erythro-
the action of cytokines, whereas, on the other hand,poiesis by blocking proliferation and differentiation of
iron is withdrawn from the erythron and shifted into theerythroid progenitor cells, affecting their ability to re-
reticuloendothelial system by the mechanisms describedspond to erythropoietin and causing deficiency in the
earlier in this article. However, erythropoietin is able toproduction of erythropoietin [6, 62, 63]. Suppression of
up-regulate TfR expression on erythroid progenitor cellserythropoiesis can also be exerted by invading pathogens
via transcriptional and post-transcriptional mechanismsitself, as shown for human immunodeficiency virus (HIV)
and therefore affects iron balance [43, 70–72]. It remainsor malaria plasmodia [64, 65]. Finally, antiproliferative
to be seen whether sequential administration of erythro-effects toward erythropoiesis have also been described
poietin and iron (such as 48 hr later) will favor a morefor ferritin [66]. This may refer to an as yet not fully
efficient uptake of iron into erythroid progenitors andunderstood mechanism by which extracellular ferritin
consecutive stimulation of erythropoiesis, so that thecauses the limitation of transferrin-mediated iron uptake
detrimental effects of this metal on the growth of patho-into erythroid progenitor cells [66]. Because cytokines
gens and down-regulation of immune effector functionare able to block hematopoiesis and, at the same time,
can be minimized.induce ferritin expression, it appears reasonable that
some of the antiproliferative actions of cytokines can be
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superior treatment of ACD is the cure of the underlying APPENDIX
disease. The supply of iron to such patients is controver-
Abbreviations used in this article are: ACD, anemia of chronic
sial [3–6, 8, 58–60], and should be avoided (at least in disease; e-ALAS, erythroid amino-levulinate synthase; IFN-g, inter-
feron-gamma; IL, interleukin; iNOS, inducible nitric oxide synthase;my opinion) in patients with chronic infectious or tumor
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IRE, iron responsive elements; IRPs, iron regulatory proteins; NO, Coordinate upregulation by iron transferrin and downregulation
by interferon gamma. J Clin Invest 91:969–976, 1993nitric oxide; TfR, serum transferrin receptor; Th-1, T-helper type-1
cells; TNF-b, tumor necrosis factor-b. 24. Hamilton T, Gray P, Adams D: Expression of the transferrin
receptor on murine peritoneal macrophages is modulated by in
vitro treatment with IFN-g. Cell Immunol 89:478–485, 1984
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